Baxalta Receives Positive CHMP Opinion for Use of ONCASPAR (pegaspargase) in European Union as a Component of Combination Therapy in Acute Lymphoblastic Leukaemia (ALL)
Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for use of ONCASPAR as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
The CHMP’s positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union. Pending EC approval, Baxalta will be authorized to market ONCASPAR in the 28 member countries of the European Union (EU), as well as Iceland, Liechtenstein and Norway.
Pending EC approval, ONCASPAR will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells responsible for more than 80 percent of childhood leukaemia cases2 - the most common type of childhood cancer.
"We are pleased to receive a positive CHMP opinion for ONCASPAR as part of a multi-agent chemotherapy regimen in paediatric and adult populations; this is a significant milestone in increasing patient access to this important biologic treatment for patients impacted by ALL," said John Orloff, M.D., head of Research & Development and chief scientific officer, Baxalta. “At Baxalta, we are committed to expanding the availability of ONCASPAR globally, and this decision makes a curative treatment available to more patients across the world.”
Today, children in the U.S. diagnosed with ALL have a survival rate of more than 90 percent – a direct result of multi-agent chemotherapy treatments. ONCASPAR is a key component of these curative therapies. Currently, there have been national licenses granted to market ONCASPAR in Argentina, Belarus, Germany, Kazakhstan, Poland, Russia, Ukraine and the United States.
About ONCASPAR (pegaspargase)
In the U.S., ONCASPAR (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the first–line treatment of patients with acute lymphoblastic leukaemia (ALL) and for the treatment of patients with ALL and hypersensitivity to native forms of L-asparaginase.
Important Safety Information for ONCASPAR
ONCASPAR is contraindicated in patients with a history of serious allergic reactions to pegaspargase, and in patients with a history of pancreatitis, serious thrombosis, or serious hemorrhagic events with prior L-asparaginase therapy.
The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) events, thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases. Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to ONCASPAR.
Patients should be observed for one hour after administration as anaphylaxis or serious allergic reactions can occur. Discontinue ONCASPAR in patients that develop pancreatitis, serious allergic reactions, or serious thrombotic events. Patients with abdominal pain should be evaluated for evidence of pancreatitis.
Serum glucose should be monitored as irreversible glucose intolerance can occur in some cases. Coagulopathy and hepatotoxicity can occur; appropriate monitoring should be performed.
Please click here to review full Product Information:
About Acute Lymphoblastic Leukaemia
Acute lymphoblastic leukaemia (ALL) is a rare, fast-growing cancer of the white blood cells, and each year there are approximately 4,000-5,000 new cases in Europe and the United States, respectively. The disease is the most common childhood cancer and is responsible for more than 80 percent of childhood leukaemia cases. The five-year paediatric survival rate has climbed to 90 percent with modern therapies.
Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing, and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta has 16,000 employees worldwide.
This release includes forward-looking statements concerning ONCASPAR, including expectations with regard to pending and future regulatory actions, commercial launch plans and potential impact on patients. Such statements are made of the date that they were first issued and are based on current expectations, beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Baxalta's control and which could cause actual results to differ materially from those in the forward-looking statements, including the following: clinical trial results; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality, manufacturing or supply issues; patient safety issues; and other risks identified in Baxalta's filings with the Securities and Exchange Commission, all of which are available on Baxalta's website. Baxalta expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
|1.||Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children’s Oncology Group. Published online March 12, 2012, in the Journal of Clinical Oncology. First author: Stephen P. Hunger, University of Colorado Cancer Center, Aurora, Colorado.|
Acute lymphoblastic leukemia. Medline Plus. 2014. Available at: www.nlm.nih.gov/medlineplus/ency/article/000541.htm .
Baxalta and Oncaspar are trademarks of Baxalta Incorporated.
Baxalta Media Relations
Kellie Hotz, +1-224-940-2202
Baxalta Investor Relations
Mary Kay Ladone, +1-224-948-3371
Lorna Williams, +1-224-948-3511
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FL-GE-AVIATION16.10.2018 00:19 | pressemeddelelse
GE’s AffinityTM: The first civil supersonic engine in 55 years – launching a new era of efficient supersonic flight
NY-IFF15.10.2018 22:17 | pressemeddelelse
IFF to Release Third Quarter 2018 Results November 5
SUMITOMO-SHI-FW15.10.2018 22:02 | pressemeddelelse
Sumitomo SHI FW Wins Contract for Biomass CFB Boiler Island in South Korea
AMPLEXOR15.10.2018 21:11 | pressemeddelelse
AMPLEXOR to Present on Neural Machine Translation Engine at Artificial Intelligence Event: 30 Years of DFKI – 30 Years of AI for Humans
KRAMER-LEVIN-NAFTALIS15.10.2018 18:56 | pressemeddelelse
Lehman Brothers Treasury to Further Explore Strategic Opportunities
SFL15.10.2018 18:30 | pressemeddelelse
SFL – Third-Quarter 2018 Financial Information
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum